HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy

Ke Liu; Jun Huang; Jiao Liu; Changfeng Li; Guido Guido Kroemer; Daolin Tang; Rui Kang

doi:10.1158/0008-5472.can-21-3917

Abstract

1 min read

This study reveals an HSP90-centric, iron-modulated mechanism that confers immunosuppression, offering potential therapeutic targets for interfering with acquired resistance to the most prevalent anticancer immunotherapies.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Preprint2023

Data from HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy

Ke Liu, Jun Huang, Jiao Liu, Changfeng Li, Guido Guido Kroemer, Daolin Tang, Rui Kang

Preprint2023

Data from HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy

Ke Liu, Jun Huang, Jiao Liu, Changfeng Li, Guido Guido Kroemer, Daolin Tang, Rui Kang

Preprint2023

Supplementary Data from HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy

Ke Liu, Jun Huang, Jiao Liu, Changfeng Li, Guido Guido Kroemer, Daolin Tang, Rui Kang

Preprint2023

Supplementary Data from HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy

Ke Liu, Jun Huang, Jiao Liu, Changfeng Li, Guido Guido Kroemer, Daolin Tang, Rui Kang

Article2019

Trial watch: dendritic cell vaccination for cancer immunotherapy

Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi, Abhishek D. Garg